摘要
目的：探讨miRNA-221在非小细胞肺癌组织中的表达及其与预后的相关性。方法：回顾性收集分析南通大学附属医院2010年1月至2012年12月期间行完全切除术治疗的153例非小细胞肺癌患者的临床资料,同时应用RT-PCR检测患者组织标本miRNA-221的表达量,分析其与患者临床资料及总生存期（OS）的关系。结果：年龄、临床分期与miRNA-221表达存在相关性,P〈0.05。单因素COX回归分析显示,临床分期（OR=1.96,95%CI：1.14-2.67）、腺癌（OR=2.54,95%CI：1.77-5.12）、肿瘤大小（OR=1.33,95%CI：1.01-2.14）和miRNA-221（OR=3.07,95%CI：1.76-6.31）表达均是影响OS的危险因素;多因素COX回归分析显示,临床分期（OR=3.32,95%CI：1.67-7.05）和miRNA-221表达（OR=2.55,95%CI：1.41-4.85）是影响OS的独立危险因素。结论：miRNA-221高表达提示非小细胞肺癌患者OS较短,有望作为肺癌预后预测的分子标志物。
Objective： To investigate the expression of miRNA-221 in non-small cell lung cancer and its correlation with prognosis. Methods： the clinical data of 153 patients from January 2010 to December 2012 with non-small cell lung cancer who were treated by surgery were retrospectively analyzed,and the expression of miRNA-221 was detected by RT-PCR analysis,and the relationship between the clinical data and the overall survival（ OS） of patients was analyzed. Results： there was a correlation between age,clinical stage and miRNA-221 expression with P〈0. 05. COX regression analysis showed that clinical staging（ OR = 1. 96,95% CI： 1. 14-2.67）,adenocarcinoma（ OR = 2. 54,95% CI： 1. 77-5. 12）,tumor size（ OR = 1. 33,95% CI： 1. 01-2. 14） and miRNA-221 expression（ OR = 3. 07,95% CI： 1. 76-6. 31） were the risk factors of OS,clinical stage（ OR = 3. 32,95% CI： 1. 67-7. 05） and miRNA-221 expression（ OR = 2. 55,95% CI： 1. 41-4. 85） were independent risk factors of OS. Conclusion： miRNA-221 highly expresses in the short-lived patients with non-small cell lung cancer,and may be expected to be a molecular marker for predicting the prognosis of lung cancer.
出处
《东南大学学报（医学版）》
CAS
北大核心
2016年第3期332-336,共5页
Journal of Southeast University(Medical Science Edition)
基金
国家自然科学基金资助项目(30771126)
